Annual Drug Patent Expirations for PRADAXA
Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from three suppliers. There are five patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for PRADAXA.
This drug has two hundred and forty-five patent family members in fifty-two countries.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. Three suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
